1. Mazurek S, Grimm H, Oehmke Weisse G, Teigelkamp S, Eigenbrodt E. Tumor M2-PK and glutaminolytic enzymes in the metabolic shift of tumor cells. Anticancer Res. 2000;20:5151–4.
2. Wu J, Hu L, Chen M, Cao W, Chen H, He T. Pyruvate kinase M2 overexpression and poor prognosis in solid tumors of digestive system: evidence from 16 cohort studies. Onco Targets Ther. 2016;9:4277–88.
3. Eigenbrodt E, Basenau D, Holthusen, Mazurek S, Fischer G. Quantification of tumor type M2 pyruvate kinase Tu M2-PK in human carcinomas. Anticancer Res. 1997;17:3153–6.
4. Hugo F, Fisher G, Eigenbrodt E. Quantitative detection of tumour M2-PK in serum and plasma. Anticancer Res. 1999;19:2753–7.
5. Oremek GM, Eigenbrodt E, Radle J, Zeuzem S, Seiffert UB. Value of the serum levels of the tumour marker Tu M2-PK in pancreatic cancer. Anticancer Res. 1997;17:3031–4.